Literature DB >> 21095069

HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component.

Ning Liao1, Guo-chun Zhang, Yan-hui Liu, Xue-rui Li, Meng Yao, Fang-ping Xu, Li Li, Yi-long Wu.   

Abstract

DCIS of the breast with coexisting invasion is commonly seen, and no consensus on any biomarker capable of discriminating this subgroup has been reached yet. We retrospectively examined the receptor status and the histological grade in Chinese DCIS patients to identify any independent predictor in order to discriminate a subgroup with coexisting invasion from pure DCIS patients. A consecutive Chinese DCIS patient cohort registered at a single institution was included for ER, PR, and HER2 status, as well as for evaluation of the histological grade. Patients with invasion foci >1cm in diameter were excluded. The HER2 gene amplification status was further examined by FISH when the IHC result was HER2 (2+). Molecular subtypes were also profiled. Age, histological grade, ER, PR, and HER2 status were included in association analyses. In total, 183 patients were included. A hundred and forty patients had pure DCIS, and 43 patients had DCIS with invasion. The luminal A subtype accounted for 49.7% of all cases, the HER2-positive subtype for 27.9%, and only 10.4% and 12.0% represented the luminal B and basal-like subtypes, respectively. Univariate analyses showed that histological Grade 2, Grade 3, and HER2-positive status were associated with DCIS with invasion, odds ratios 5.1 (P = 0.017), 5.2 (P = 0.01) and 3.34 (P = 0.001), respectively. However, only the HER2-positive status was of statistical significance in the multivariate logistic regression analyses after adjustment for other markers, odds ratio 3.8 (95%CI 1.4-10, P = 0.008). The 43 cases with invasion were further stratified into extensive or small DCIS components according to the percentage of DCIS to total tumor area using 25% as the cutoff point. Multinomial logistic regression with pure DCIS cases as reference showed that the HER2-positive status was associated only with the group showing an extensive DCIS component, odds ratio 6.2 (95%CI 1.8-21, P = 0.003), but not with the group having a small DCIS component. Our study demonstrates that HER2-positive status is an independent predictor for DCIS, with invasion presenting an extensive DCIS component, and favors the hypothesis that HER2 overexpression or gene amplification is involved in the transition from DCIS to invasive disease.
Copyright © 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21095069     DOI: 10.1016/j.prp.2010.08.005

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  11 in total

1.  Potential use of vaccines in the primary prevention of breast cancer in high-risk patients.

Authors:  Matteo Lazzeroni; Davide Serrano
Journal:  Breast Care (Basel)       Date:  2012-08       Impact factor: 2.860

2.  The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease.

Authors:  Shuko Harada; Rosemarie Mick; Robert E Roses; Holly Graves; Huilin Niu; Anupama Sharma; Jeanne E Schueller; Harvey Nisenbaum; Brian J Czerniecki; Paul J Zhang
Journal:  J Surg Oncol       Date:  2011-05-09       Impact factor: 3.454

3.  Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients.

Authors:  Guo-Chun Zhang; Xue-Ke Qian; Zi-Bai Guo; Chong-Yang Ren; Meng Yao; Xue-Rui Li; Kun Wang; Jian Zu; Ning Liao
Journal:  Med Oncol       Date:  2012-05-01       Impact factor: 3.064

4.  Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile.

Authors:  Satoshi Takahashi; Aye Aye Thike; Valerie Cui Yun Koh; Hironobu Sasano; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2018-07-23       Impact factor: 4.064

5.  Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer.

Authors:  G C Zhang; Y F Zhang; F P Xu; X K Qian; Z B Guo; C Y Ren; M Yao
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

6.  Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype.

Authors:  Mieke Van Bockstal; Kathleen Lambein; Hannelore Denys; Geert Braems; Ann Nuyts; Rudy Van den Broecke; Veronique Cocquyt; Olivier De Wever; Louis Libbrecht
Journal:  Virchows Arch       Date:  2014-06-29       Impact factor: 4.064

7.  Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial.

Authors:  Mangesh A Thorat; Pauline M Levey; J Louise Jones; Sarah E Pinder; Nigel J Bundred; Ian S Fentiman; Jack Cuzick
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 12.531

8.  Aldehyde dehydrogenase 1 expression correlates with the invasion of breast cancer.

Authors:  Hong Pan; Naping Wu; Yaoyu Huang; Qin Li; Chenghao Liu; Mengdi Liang; Wenbin Zhou; Xiaoan Liu; Shui Wang
Journal:  Diagn Pathol       Date:  2015-06-13       Impact factor: 2.644

9.  The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.

Authors:  Signe Borgquist; Wenjing Zhou; Karin Jirström; Rose-Marie Amini; Thomas Sollie; Therese Sørlie; Carl Blomqvist; Salma Butt; Fredrik Wärnberg
Journal:  BMC Cancer       Date:  2015-06-11       Impact factor: 4.430

10.  T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells.

Authors:  Prachi Namjoshi; Lori Showalter; Brian J Czerniecki; Gary K Koski
Journal:  Oncotarget       Date:  2019-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.